Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Investigational New Drugs
Published in: Investigational New Drugs 3/2005

01-06-2005

Randomized phase II evaluation of aprinocarsen in combination with gemcitabine and cisplatin for patients with advanced/metastatic non-small cell lung cancer

Authors: Johan Vansteenkiste, Jean-Luc Canon, Henrik Riska, Robert Pirker, Patrick Peterson, William John, Pekka Mali, Michael Lahn

Published in: Investigational New Drugs | Issue 3/2005

Login to get access
Metadata
Title
Randomized phase II evaluation of aprinocarsen in combination with gemcitabine and cisplatin for patients with advanced/metastatic non-small cell lung cancer
Authors
Johan Vansteenkiste
Jean-Luc Canon
Henrik Riska
Robert Pirker
Patrick Peterson
William John
Pekka Mali
Michael Lahn
Publication date
01-06-2005
Publisher
Kluwer Academic Publishers
Published in
Investigational New Drugs / Issue 3/2005
Print ISSN: 0167-6997
Electronic ISSN: 1573-0646
DOI
https://doi.org/10.1007/s10637-005-6736-x

Other articles of this Issue 3/2005

Investigational New Drugs 3/2005 Go to the issue

OriginalPaper

Multi-centre Phase II trial of the polyamine synthesis inhibitor SAM486A (CGP48664) in patients with metastatic melanoma

OriginalPaper

A phase I trial of irinotecan (CPT-11) with amifostine in patients with metastatic colorectal cancer

OriginalPaper

Semi-physiological model describing the hematological toxicity of the anti-cancer agent indisulam

OriginalPaper

Phase II trial of dolastatin-10 in patients with advanced breast cancer

OriginalPaper

Induction of apoptosis by flavopiridol unrelated to cell cycle arrest in germ cell tumour derived cell lines

OriginalPaper

Phase I trial of menadiol diphosphate (vitamin K3) in advanced malignancy
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits